About Sight Sciences
Sight Sciences is a publicly listed company based in Menlo Park (United States) founded in 2006. Surgical systems for ophthalmological disease treatment are developed. Sight Sciences has raised $128.59 million across 10 funding rounds from investors including Janus Henderson Investors, MidCap Financial and KCK MedTech. The company has 216 employees. Its focus areas include Life Sciences, Ophthalmology, Medical Devices and Therapy. Its legal entity is SIGHT SCIENCES, INC. Its competitors include Alcon, Iantrek and Orbit Biomedical; 3 of its 3 listed competitors have raised funding.
Company details
Sight Sciences was established in 2006 in Menlo Park, United States, within the medical device sector focused on ophthalmology. Surgical instruments and systems are created for managing conditions like primary open-angle glaucoma, Meibomian Gland Dysfunction, dry eye, and blepharitis. These tools support canaloplasty procedures aimed at lowering intraocular pressure among adult patients, with operations centered on innovation in eye care technologies.
- Headquarters Menlo Park, United States
- Employees 216
- Stage Public
- SectorsHealthcare
- Website sightsciences.com
- Legal Name Sight Sciences, Inc.
- Annual Revenue$77.36 M (USD)-3.13as on Dec 31, 2025
- Net Profit-$38.43 M (USD)25.4as on Dec 31, 2025
- EBITDA-$36.61 M (USD)26.51as on Dec 31, 2025
- Total Equity Funding$128.59M (USD)
in 10 rounds
- Latest Funding Round$23.25M (USD), Series E
Dec 2020
- InvestorsJanus Henderson Investors
& 5 more
- Employee Count216
Funding Insights of Sight Sciences
Sight Sciences has successfully raised a total of $128.59M across 10 strategic funding rounds. The most recent funding activity was a Series E round of $23.25 million completed in December 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $128.59M
- Total Rounds 10
- Last Round Series E — $23.25M
- First Round $524,995
(Sep 2011)
- Investors Count 6
All 10 funding rounds of Sight Sciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2020 | $23.25M | Series E | – | Janus Henderson Investors | – |
| Dec 2020 | Debt – Conventional | – | – | ||
| Mar 2020 | $30.15M | Series E | – | – | – |
| Sep 2019 | $31M | Series D | – | KCK MedTech | |
| Jun 2019 | $25M | Debt – Conventional | – | – | |
| May 2018 | $19.73M | Series C | – | – | – |
| Oct 2017 | $10M | Series C | – | Allegro Investment Fund | |
| Mar 2016 | $7M | Series B | – | – | |
| Oct 2015 | $6.94M | Series A | – | – | |
| Sep 2011 | $524,995 | Seed | – | – | – |
6 investors in total: 6 institutional.
Investors in Sight Sciences
Sight Sciences has secured backing from 6 investors, including venture fund investors. Prominent investors backing the company include Janus Henderson Investors, MidCap Financial and KCK MedTech.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Multiple sectors are targeted for venture capital investments. | 1934 | janushenderson.com | London, United Kingdom | |
Private debt funds are managed across multiple sectors. | 2008 | midcapfinancial.com | Bethesda, United States | |
| kckmedtech.com | ||||
A private investment fund supporting entrepreneurial businesses with strategic resources. | allegroinvestment.com | Menlo Park, USA | ||
A venture capital firm focused on early-stage MedTech investments. | 2006 | shdpartners.com | Dallas, United States | |
Allegro Investment Fund is involved in investment activities. | allegroinvestmentfund.com |
Investor details for Sight Sciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Sight Sciences
138 people are tracked at Sight Sciences (46 in leadership, 6 in board & advisors, 86 in team); the tracked headcount is 216.
| Name | Role | Group |
|---|---|---|
Reay H. Brown | Chief Medical Officer | Leadership |
Beau Bjorland | Associate Regional Director | Leadership |
David Badawi | Founder & CTO | Leadership |
Shawn Hay | Regional Sales Director, Surgical | Leadership |
Kathy Chester | VP, Regulatory Affairs | Leadership |
Steve R. Tamayo Jr. | VP & Chief Ethics & Compliance Officer | Leadership |
Alessandro Vescovo | Director Of International Sales Eumea | Leadership |
Mark Papini | VP, Glaucoma Sales | Leadership |
Matt Gibson | Sr. Director Of Marketing, Dry Eye | Leadership |
Daniel O'Keeffe | VP, Research & Development | Leadership |
Jeremy Hayden | General Counsel & Chief Compliance Officer | Leadership |
Rob Hill | VP, International Sales | Leadership |
Harry Pierre Simon | VP, Marketing, Glaucoma | Leadership |
Jim Rodberg | VP of Finance & Corporate Controller | Leadership |
Ali Bauerlein | CFO | Leadership |
Mary Cantu | VP, Global Market Access | Leadership |
Brenton Taylor | Executive VP Operations And Research & Development | Leadership |
Mistie Girard | Sr Director Payor Relations & Reimbursement | Leadership |
Chris Pike | VP, IT | Leadership |
Kole Goodchild | VP, Financial Planning & Analysis & Sales Operations | Leadership |
118 more people are available in the full profile.
Complete people profiles for Sight Sciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Sight Sciences
Sight Sciences is a publicly listed company on the NASDAQ with ticker symbol SGHT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date15 Jul 2021
- Listed onNASDAQ: SGHT
- Listed entitySight Sciences, Inc.
- Exchange sectorHealth technology
- ISINUS82657M1053
- Share price$8.39 (-6.41% on the day) · 2026-10-13
- Market capitalisation$462.2M
- EPS (diluted, trailing year)$-0.56
- Volume (last session)413,505
Financials of Sight Sciences
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $77.4M | -$38.4M | -$36.6M |
| 2024 | $79.9M | -$51.5M | -$49.8M |
| 2023 | $81.1M | -$55.5M | -$56.7M |
| 2022 | $71.3M | -$86.2M | -$82.7M |
| 2021 | $49.0M | -$63.0M | -$50.3M |
Detailed financial statements for Sight Sciences
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Sight Sciences
4 dated milestones of Sight Sciences across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Sight Sciences is founded.
- Funding First funding round of $525K.
- Funding Latest funding round, Series E, of $23.2M.
- IPO Lists on the stock exchange (IPO).
Competitors of Sight Sciences
Sight Sciences has 3 listed competitors in our database, 3 of them funded. They include Alcon, Iantrek and Orbit Biomedical.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| alcon.com | 1945 | Fort Worth, United States | $171.61M | 25,315 | Developer of a wide range of eye care products | |
| iantrekmed.com | 2019 | White Plains, United States | $67.78M | 2 | Developer of a minimally invasive eye surgery technology | |
| orbitbiomedical.com | 2018 | Ambler, United States | $12M | Medical device for ophthalmic surgery is developed. |
Detailed competitors of Sight Sciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Sight Sciences
The website of Sight Sciences (sightsciences.com) receives about 3.7K visits a month.
- Monthly visits3.7K
▼ 13% vs previous month
Top companies in Ophthalmology
3 companies that operate in the same segment as Sight Sciences (Ophthalmology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of a wide range of eye care products | 1945 | Fort Worth, Texas, United States | USD 171.61 M | USD 9.64 B | 25,600 | |
Genetic medicines are developed by 4DMT for transformative therapies. | 2013 | Emeryville, California, United States | USD 186.59 M | USD 85.21 M | 227 | |
Developer of antibodies to treat complement-mediated neurodegenerative diseases | 2011 | San Francisco, California, United States | USD 256 M | 100 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Sight Sciences
Complete news archive for Sight Sciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sight Sciences
Sight Sciences was founded in 2006 and raised its 1st funding round 5 years after it was founded.
Sight Sciences is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Sight Sciences is a funded company, having raised a total of $128.59M across 10 funding rounds to date. The company's 1st funding round was a Seed of $525K, raised on Sep 2011.
Sight Sciences has 216 employees.
Annual revenue of Sight Sciences is $77.36M as on Dec 31, 2025.
Sight Sciences was established in 2006 in Menlo Park, United States, within the medical device sector focused on ophthalmology. Surgical instruments and systems are created for managing conditions like primary open-angle glaucoma, Meibomian Gland Dysfunction, dry eye, and blepharitis. These tools support canaloplasty procedures aimed at lowering intraocular pressure among adult patients, with operations centered on innovation in eye care technologies.
Sight Sciences's top competitors include Alcon, Iantrek and Orbit Biomedical.
Yes, Sight Sciences is publicly traded on NASDAQ under the ticker symbol SGHT.
Sight Sciences has 6 investors. Key investors include Janus Henderson Investors, MidCap Financial, KCK MedTech, Allegro Investment Fund, and SHD Partners.
Sight Sciences operates through Sight Sciences, Inc..